<DOC>
	<DOCNO>NCT02340403</DOCNO>
	<brief_summary>Neurotoxic chemotherapy , include oxaliplatin , responsible disable neuropathic pain last month even year end chemotherapy . Currently , effective neuroprotective treatment prevent relieve pain . The strategy reduction oxaliplatin dose premature discontinuation therapy , risk burden prognosis remission . Thus , good understand pathophysiology iatrogenic neuropathy appear necessary order discover new potential therapeutic target . Preclinical work able demonstrate important metabolic change certain brain structure animal model oxaliplatin-induced neuropathy . A significant increase choline concentration find posterior insular cortex neuropathic animal compare control animal . Furthermore , concentration choline positively correlate nociceptive threshold . Thus , neuropathic pain induce oxaliplatin would involve posterior insular cortex would associate increase choline concentration level . Clinical translation preclinical result feasible practice since choline concentration determine brain non-invasive magnetic resonance spectroscopy .</brief_summary>
	<brief_title>Exploration NMR Spectroscopy Choline Concentrations Insular Cortex Patients Suffering Neuropathic Pain Induced Oxaliplatin</brief_title>
	<detailed_description>The objective study demonstrate significant increase choline concentration insular cortex patient oxaliplatin induced neuropathy . Other objective assess correlation metabolite concentration insular cortex frequency / intensity pain neuropathic symptom , cold heat-induced pain comorbidities ( anxiety , pain , quality life ) .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Choline</mesh_term>
	<criteria>Oxaliplatin treat patient suffer neuropathic pain Chemotherapy ( oxaliplatin base ) end Pain VAS ≥ 3/10 , 1 month chemotherapy end DN4 interview score ≥ 3/7 , 1 month chemotherapy end Oxaliplatin treat patient without neuropathic pain Chemotherapy ( oxaliplatin base ) end Pain VAS &lt; 3/10 , 1 month chemotherapy end DN4 interview score &lt; 3/7 , 1 month chemotherapy end All patient righthanded No contrindication MRI Free , write informed consent Affiliated french health system Effective contraception male female childbearing age Performance score ( WHO ) ≤ 2 Age &lt; 18 Lefthanded BMI &gt; 30 kg/m² Amputees part upper limb Diabetic patient Painful event schedule enrollment ( eg . surgical resection ) Neurological disease ( eg Parkinson 's disease , stroke , migraine , fibromyalgia ... ) Chronic pain history chemotherapy Analgesic treatment paracetamol weak opioids Alcohol consumption &gt; 3 units/day ( 30 g/day ) men &gt; 2 units/day ( 20 g/day ) woman Any unbalanced progressive disease ( hepatic failure , renal impairment ( creatinine clearance &lt; 30 mL/min ) , respiratory failure , congestive heart failure , myocardial infarction within past 6 month ... ) All active cancer Patient pacemaker , cochlear implant , metal implant , magnetic element Claustrophobia Pregnant lactation Legal incapacity ( person deprive liberty guardianship ) Psychological , social , family geographical reason incompatible study Already include another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Neuropathy</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Insula</keyword>
	<keyword>choline</keyword>
</DOC>